Viridian Therapeutics, Inc. VRDN Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s interest coverage?
- Viridian Therapeutics, Inc. (VRDN) reported interest coverage of -49.3× in Q1 2026.
- How has Viridian Therapeutics, Inc.'s interest coverage changed year-over-year?
- Viridian Therapeutics, Inc.'s interest coverage increased by 67.9% year-over-year, from -153.7× to -49.3×.
- What is the long-term trend for Viridian Therapeutics, Inc.'s interest coverage?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s interest coverage has grown at a -19.4% compound annual growth rate (CAGR), from -217.3× to -74.1×.
- What does interest coverage mean?
- Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.